We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Japanese pharma company says Medicago’s product will be cheaper to make and easier to transport
Cigarette maker secures majority of shares in UK-based medical device manufacturer
Shareholders in UK inhaler maker will have final say in a takeover battle that has divided opinion
We must allow companies to reinvent themselves and address the problems they helped create
Short-term rental provider reports strong revenue growth, but warns on spread of Covid variants
Inhaler maker draws criticism from health charity for ‘absurd’ deal
UK inhaler group has bungled handling competing interests from cigarette-maker Philip Morris and Carlyle
UK regulator to oversee five days of bidding for Vectura by cigarette producer and private equity firm
Tobacco group lifts bid above £1bn in battle with Carlyle as private equity targets British businesses
Brand ‘will disappear’ from UK shelves under diversification strategy, says chief executive
Philip Morris International’s deal to buy inhaler company Vectura creates confusion on both sides
Many groups are diversifying but the traditional smoking business is still the big money spinner
A danger for the tobacco group is expanding wholesale into industries where similarities with its core business are only superficial
Tobacco giant gatecrashes agreement with Carlyle in quest to become ‘healthcare and wellness’ group
Former employee suing US foundation argues support for vaping is a boost for cigarette makers
Scrutiny of e-cigarettes casts cloud over deals between Big Tobacco and motorsports
Welcome to Due Diligence, the FT’s daily deals briefing
Souring taste of Juul cuts appetite for deal
Juul ousts CEO and suspends US ads as Philip Morris International and Altria end $200bn merger talks
Health officials have increased scrutiny of vaping after lung illnesses and deaths
The lasting value of the two Marlboro makers has surprised and dismayed public health advocates
Ambitions to combine the companies behind the Marlboro brand raise concerns on Wall Street
Move to recombine comes a decade after companies split into US and international arms
Tobacco companies face challenge in convincing investors of merits of $200bn deal
The case for re-unification lies in the push for tobacco alternatives
International Edition
